Efficacy of Remimazolam for induction and maintenance of general anesthesia with laryngeal mask in patients undergoing otorhinolaryngology surgery
WANG Huijun1 XIONG Jun2 BAO Yin1 XI Chunhua1 WANG Guyan1
1.Department of Anesthesiology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China;
2.Department of Anesthesiology, Shenzhen University General Hospital, Guangdong Province, Shenzhen 518055, China
Abstract：Objective To evaluate the efficacy of Remimazolam for induction and maintenance of laryngeal mask general anesthesia in patients undergoing otorhinolaryngology surgery, and to explore a new general anesthesia model that can be safely used in day surgery. Methods A total of 114 patients of undergoing otorhinolaryngology surgery under laryngeal mask general anesthesia admitted to Beijing Tongren Hospital from April 2021 to February 2022. They were divided into Propofol group and Remimazolam group using a random number table method, with 57 cases in each group. At the beginning of induction, intravenously infusing Sufentanil 0.2 μg/kg, Propofol 2 mg/kg was injected in Propofol group, Remimazolam 0.3 mg/kg was injected in Remimazolam group, Rocuronium 0.6 mg/kg was injected after the patients consciousness disappeared, laryngeal mask intubation was performed. Anesthesia was maintained by intravenously injecting Propofol 4-8 mg/(kg·h) in Propofol group and Remimazolam 1-3 mg/(kg·h) in Remimazolam group. Bispectralindexvalues (BIS) was maintained at 40-60. The time of sedation induction, recovery time of consciousness, time of laryngeal mask extubation and residence time in postanesthesia care unit (PACU) were recorded; the MAP and HR before induction(T0), before laryngeal mask implantation (T1), after laryngeal mask implantation (T2), before surgery (T3), at drug withdrawal(T4) and at laryngeal mask removal (T5) were recorded; the occurrence of injection pain during induction of anesthesia, intraoperative and postoperative complications were recorded. Results The success rate of sedation in both groups was 100%. The sedation induction time of Remimazolam group was higher than that of Propofol group, and the incidence of injection pain, intraoperative hypotension, and bradycardia during induction was lower than that of Propofol group, and the differences were statistically significant (P ＜ 0.05); there was no significant difference in consciousness recovery time, laryngeal mask removal time, PACU residence time, postoperative tachycardia, and postoperative nausea and vomiting between the two groups (P ＞ 0.05). There was no significant difference in MAP between the two groups at T0 (P ＞ 0.05); the MAP value of T1-T5 in both groups was lower than that of T0, but that of Remimazolam group was higher than that of Propofol group, and the differences were statistically significant (P ＜ 0.05); there was no significant difference in HR between the two groups at T0 (P ＞ 0.05); the HR values at T1 and T5 in Remimazolam group were higher than those in Propofol group, and the difference was statistically significant (P ＜ 0.05); the HR value of Propofol group at T1-T4 was lower than that at T0, and the difference was statistically significant (P ＜ 0.05); there was no significant difference between the HR values at T1, T2, T5, and T0 in Remimazolam group (P ＞ 0.05); no intraoperative hypertension and intraoperative awareness were found in both groups. No other complications were found during in PACU and within 24 h after operation. Conclusion Remimazolam can be safely and effectively used in the induction and maintenance of laryngeal mask general anesthesia in otorhinolaryngology surgery, which is more helpful to maintain the stability of hemodynamics and reduce the incidence of adverse reactions.
王惠军1 熊军2 包音1 奚春花１ 王古岩1. 瑞马唑仑用于五官科手术患者喉罩全身麻醉的效果[J]. 中国医药导报, 2022, 19(24): 115-118,123.
WANG Huijun1 XIONG Jun2 BAO Yin1 XI Chunhua1 WANG Guyan1. Efficacy of Remimazolam for induction and maintenance of general anesthesia with laryngeal mask in patients undergoing otorhinolaryngology surgery. 中国医药导报, 2022, 19(24): 115-118,123.
[1] 俞德梁，刘小南，高博欣，等.计划性手术模式：日间手术管理的新实践[J].中国卫生质量管理，2021，28（7）：37-39，47.
[2] Jiang LS，Houston R，Li C，et al. Day Surgery Program at West China Hospital：Exploring the Initial Experience [J]. Cureus，2020，12（7）：e8961.
[3] Wu XK，Zhao ZJ，Sun HL，et al. Day-surgery percutaneous nephrolithotomy：a high-volume center retrospective experience [J]. World J Urol，2020，38（5）：1323-1328.
[4] Eleveld DJ，Colin P，Absalom AR，et al. Pharmacokinetic-pharmacodynamic model for propofol for broad application in anaesthesia and sedation [J]. Br J Anaesth，2018，120（5）：942-959.
[5] Sahinovic MM，Struys MMRF，Absalom AR. Clinical Pharmacokinetics and Pharmacodynamics of Propofol [J]. Clin Pharmacokinet，2018，57（12）：1539-1558.
[6] Schuttler J，Eisenried A，Lerch M，et al. Pharmacokinetics and pharmacodynamics of remimazolam （CNS 7056） after continuous infusion in healthy male tolunteers [J]. Anesthesiology，2020，132（4）：636-651.
[7] Sneyd JR，Rigby-Jones AE. Remimazolam for anaesthesia or sedation [J]. Curr Opin Anaesthesiol，2020，33（4）：506-511.
[8] 赵颖颖，李锋.瑞马唑仑与丙泊酚用于无痛胃肠镜检查临床比较[J].国际麻醉学与复苏杂志，2021，42（9）：924-927.
[9] Dai GR，Pei LL，Duan FY，et al. Safety and efficacy of remimazolam compared with propofol in induction of general anesthesia [J]. Minerva Anestesiol，2021，87（10）：1073-1079.
[10] 杨文芳，孙莉.改良警觉与镇静评分在无痛腔镜诊疗中的应用价值[J].中国肿瘤临床与康复，2012，19（2）：157-159.
[11] Jeon Y. Reduction of pain on injection of propofol：combination of nitroglycerin and lidocaine [J]. J Anesth，2012，26（5）：728-731.
[12] Belleudy S，Kérimian M，Legrenzi P，et al. Assessment of quality and safety in rhinologic day surgery [J]. Eur Ann Otorhinolaryngol Head Neck Dis，2021，138（3）：129-134.
[13] 李海鹏，葛锋.日间手术存在的问题与优化策略探讨[J].中国医院管理，2022，42（6）：64-66.
[14] 胡洁，张瑞冬，白洁.氯胺酮复合异丙酚麻醉用于小儿五官科日间手术的分析[J].医学临床研究，2011，28（4）：611-613.
[15] Sneyd JR，Rigby JAE. Remimazolam for anaesthesia or sedation [J]. Curr Opin Anaesthesiol，2020，33（4）：506-511.
[16] Keam SJ. Remimazolam：First Approval [J]. Drugs，2020， 80（6）：625-633.
[17] Rex DK，Bhandari R，Lorch DG，et al. Safety and efficacy of remimazolam in high risk colonoscopy：A randomized trial [J]. Dig Liver Dis，2021，53（1）：94-101.
[18] Doi M，Morita K，Takeda J，et al. Efficacy and safety of remimazolam versus propofol for general anesthesia：a multicenter，single-blind，randomized，parallel-group，phase Ⅱb/Ⅲ trial [J]. J Anesth，2020，34（4）：543-553.
[19] 李薇，韩晟，申慧明，等.原研和仿制丙泊酚中/长链脂肪乳的医疗资源使用分析[J].中国医院用药评价与分析，2019，（12）：1491-1493，1499.
[20] Rex DK，Deenadayalu V，Eid E. Gastroenterologist-directed propofol：an update [J]. Gastrointest Endosc Clin N Am，2008，18（4）：717-725，ix.
[21] Wang W，Wu L，Zhang C，et al. Is propofol injection pain really important to patients? [J]. BMC Anesthesiol，2017， 17（1）：24.
[22] Saraghi M，Badner VM，Golden LR，et al. Propofol：an overview of its risks and benefits [J]. Compend Contin Educ Dent，2013，34（4）：252-258.
[23] Kilpatrick GJ. Remimazolam：Non-Clinical and Clinical Profile of a New Sedative/Anesthetic Agent [J]. Front Pharmacol，2021，20（12）：690875.
[24] 陈瑜，蔡姝，朱晓刚，等.瑞马唑仑用于老年患者全麻诱导时的镇静效果[J].中华麻醉学杂志，2020，40（8）：974-976.
[25] 王春艳，于泳浩.瑞马唑仑临床研究进展[J].中华麻醉学杂志，2019，39（3）：261-263.
京公网安备 11010502046598号